Ranbaxy Daiichi Deal
- All
- News
- Videos
-
Supreme Court Asks Lenders To Place Loan Records Of Former Ranbaxy Promoters
The apex court on November 15, 2019 had held former Ranbaxy promoters guilty of contempt of court for violating its order asking them not to divest their shares in FHL.
-
Ranbaxy Ex-Promoters Malvinder, Shivinder Singh Raided In Fraud Case
Malvinder Singh and his brother Shivinder Singh, ex-promoters of pharmaceutical giant Ranbaxy, were raided today by the Enforcement Directorate in a Rs 740-crore fraud case. against the former promoters of pharmaceutical company Ranbaxy, Malvinder Mohan Singh and his brother Shivinder Mohan Singh.
-
Former Ranbaxy Owners Malvinder, Shivinder Mohan Singh Fined Rs 2,600 Crore
Billionaire Malvinder Mohan Singh and his younger brother Shivinder Mohan Singh have been asked to pay nearly Rs 2,600 crore in fine to Daiichi Sankyo, for "suppressing and misrepresenting" facts about the 2008 deal involving the sale of controlling stake in Ranbaxy to the Japanese drugmaker.
-
Japan's Daiichi Sankyo To Sell Up To $3.6 Billion Sun Pharma Stake: Report
The Japanese company is selling its 8.9 per cent stake in Sun Pharma, India's largest drugmaker by sales, via block deals on the Indian exchanges, said the person, who declined to be named as he was not authorised to speak to the media.
-
2014: Pharma Deals Worth Billions, Fines Worth Millions
It has been a year of bitter medicine for Indian pharmaceutical companies with fines worth millions of dollars imposed by various foreign regulators, even as they stitched together deals worth billions of dollars, including a high profile merger between Sun Pharma and Ranbaxy.
-
Ranbaxy-Sun Pharma merger deal may close by year end: Daiichi
The $4 billion merger deal of Ranbaxy with Sun Pharma is expected to close by the end of 2014, Japanese drug maker Daiichi Sankyo, which holds majority stake in the former, said today.
-
Sun Pharma soars 8% on upgrades after Ranbaxy deal
Global investment bank UBS upgraded both Sun Pharma (target Rs 720) and Ranbaxy (target Rs 576) to 'buy' citing 5-10 per cent earning per share accretion in FY17.
-
Daiichi the only loser in Sun Pharma, Ranbaxy deal: Adige
Ramesh Adige, former executive director of Ranbaxy told NDTV's Prashant Nair that Sun Pharma's acquisition of Ranbaxy for $3.2 billion is a win-win situation for all stakeholders, except Daiichi, which is the controlling shareholder in Ranbaxy.
-
Sun Pharma shares soar 4% on Ranbaxy deal
Shares in Ranbaxy, however, dropped as much as 5.5 per cent on profit taking. Ranbaxy shares have gained 26 per cent over the last week as compared to a 0.12 per cent drop in the BSE Sensex. Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy. The exchange ratio represents an implied value of Rs 457 for each Ranbaxy ...
-
Sun Pharma to acquire Ranbaxy in $4 billion all-stock deal
Ranbaxy, India's biggest company by sales, is controlled by Japan's Daiichi Sankyo. All of its local units have been under the scanner of the US Food and Drug Administration for manufacturing violations. Currently, Ranbaxy cannot export generic drugs to the US, which is its most important market.
-
Sun Pharma to acquire Ranbaxy in $4 billion all-stock deal
Mumbai-based Sun Pharma will acquire troubled Indian drug maker Ranbaxy in a US$ 4 billion all-stock transaction, the company said in a statement on Monday.
-
Supreme Court Asks Lenders To Place Loan Records Of Former Ranbaxy Promoters
The apex court on November 15, 2019 had held former Ranbaxy promoters guilty of contempt of court for violating its order asking them not to divest their shares in FHL.
-
Ranbaxy Ex-Promoters Malvinder, Shivinder Singh Raided In Fraud Case
Malvinder Singh and his brother Shivinder Singh, ex-promoters of pharmaceutical giant Ranbaxy, were raided today by the Enforcement Directorate in a Rs 740-crore fraud case. against the former promoters of pharmaceutical company Ranbaxy, Malvinder Mohan Singh and his brother Shivinder Mohan Singh.
-
Former Ranbaxy Owners Malvinder, Shivinder Mohan Singh Fined Rs 2,600 Crore
Billionaire Malvinder Mohan Singh and his younger brother Shivinder Mohan Singh have been asked to pay nearly Rs 2,600 crore in fine to Daiichi Sankyo, for "suppressing and misrepresenting" facts about the 2008 deal involving the sale of controlling stake in Ranbaxy to the Japanese drugmaker.
-
Japan's Daiichi Sankyo To Sell Up To $3.6 Billion Sun Pharma Stake: Report
The Japanese company is selling its 8.9 per cent stake in Sun Pharma, India's largest drugmaker by sales, via block deals on the Indian exchanges, said the person, who declined to be named as he was not authorised to speak to the media.
-
2014: Pharma Deals Worth Billions, Fines Worth Millions
It has been a year of bitter medicine for Indian pharmaceutical companies with fines worth millions of dollars imposed by various foreign regulators, even as they stitched together deals worth billions of dollars, including a high profile merger between Sun Pharma and Ranbaxy.
-
Ranbaxy-Sun Pharma merger deal may close by year end: Daiichi
The $4 billion merger deal of Ranbaxy with Sun Pharma is expected to close by the end of 2014, Japanese drug maker Daiichi Sankyo, which holds majority stake in the former, said today.
-
Sun Pharma soars 8% on upgrades after Ranbaxy deal
Global investment bank UBS upgraded both Sun Pharma (target Rs 720) and Ranbaxy (target Rs 576) to 'buy' citing 5-10 per cent earning per share accretion in FY17.
-
Daiichi the only loser in Sun Pharma, Ranbaxy deal: Adige
Ramesh Adige, former executive director of Ranbaxy told NDTV's Prashant Nair that Sun Pharma's acquisition of Ranbaxy for $3.2 billion is a win-win situation for all stakeholders, except Daiichi, which is the controlling shareholder in Ranbaxy.
-
Sun Pharma shares soar 4% on Ranbaxy deal
Shares in Ranbaxy, however, dropped as much as 5.5 per cent on profit taking. Ranbaxy shares have gained 26 per cent over the last week as compared to a 0.12 per cent drop in the BSE Sensex. Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy. The exchange ratio represents an implied value of Rs 457 for each Ranbaxy ...
-
Sun Pharma to acquire Ranbaxy in $4 billion all-stock deal
Ranbaxy, India's biggest company by sales, is controlled by Japan's Daiichi Sankyo. All of its local units have been under the scanner of the US Food and Drug Administration for manufacturing violations. Currently, Ranbaxy cannot export generic drugs to the US, which is its most important market.
-
Sun Pharma to acquire Ranbaxy in $4 billion all-stock deal
Mumbai-based Sun Pharma will acquire troubled Indian drug maker Ranbaxy in a US$ 4 billion all-stock transaction, the company said in a statement on Monday.
